康諾亞(2162.HK)大漲近10% 與諾誠健華合作發力First-in-class藥物開發
格隆匯9月6日丨康諾亞-B(2162.HK)今日跳空上漲,盤中一度漲近10%報55.5港元,市值155億港元。週末消息顯示,康諾亞與諾誠健華簽署戰略合作協議。據悉,雙方將發揮各自優勢,實現在新藥研發領域上的合作共贏,共同致力於開發First-in-class(同類首創)大分子創新藥造福患者。此前,諾誠健華與康諾亞按50:50比例成立了合資企業天諾健成,以在全球範圍內發現、開發及商業化相關創新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.